Lyudmila A. Bazhenova, MD

Articles

Dr. Bazhenova on the Importance of Testing for HER2 Mutations in Lung Cancer

March 31st 2021

Lyudmila A. Bazhenova, MD, discusses the importance of testing for HER2 mutations in lung cancer.

Dr. Bazhenova on a Correlative Analysis of the KRYSTAL-1 Trial in Advanced NSCLC

March 26th 2021

Lyudmila A. Bazhenova, MD, discusses the results of a preliminary exploratory correlative analysis of the phase 1/2 KRYSTAL-1 trial in advanced non–small cell lung cancer.

Dr. Bazhenova on Ongoing Clinical Trials With Immunotherapy in NSCLC

May 28th 2020

Lyudmila A. Bazhenova, MD, discusses ongoing clinical trials in non–small cell lung cancer that are investigating the utility of immunotherapy.

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

May 20th 2020

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

May 19th 2020

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Dr. Bazhenova on New Developments in RET-Rearranged NSCLC

July 28th 2019

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses new developments in RET-rearranged non–small cell lung cancer.

Dr. Bazhenova on Sequential Use of Immunotherapy and EGFR TKIs in Lung Cancer

June 11th 2019

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses research that has looked at the use of EGFR TKIs after immunotherapy in patients with EGFR-mutant non–small cell lung cancer.

Dr. Bazhenova on Sequencing Beyond Progression in EGFR-Mutant NSCLC

May 30th 2019

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses sequencing beyond progression on osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Bazhenova on Prevalence of NTRK Mutations in NSCLC and Emerging Treatments

July 27th 2018

Lyudmila A. Bazhenova, MD, medical oncologist professor of medicine, University of California, San Diego, discusses the prevalence of NTRK mutations in non–small cell lung cancer.